羟甲唑啉联合布地奈德鼻喷剂治疗慢性鼻塞的随机临床试验
这项单中心双盲随机临床试验纳入60例既往局部激素治疗失败的慢性鼻塞成人,比较羟甲唑啉/布地奈德联合喷剂与单用布地奈德治疗4周后再减量3周的疗效。联合组应答率83%(24/29),单用布地奈德组36%(10/28),差异47个百分点(95%CI 25-70)。联合组未出现反跳性鼻塞症状,全部成功停用羟甲唑啉。
要点
- 局部激素治疗失败的慢性鼻塞患者,联合羟甲唑啉/布地奈德4周应答率显著高于单用布地奈德。
- 研究期间联合组无药物性鼻炎症状或组织学证据,全部成功减停羟甲唑啉。
- 更长疗程使用羟甲唑啉的反跳风险尚不能排除,需谨慎评估。
核心结论
- 对局部激素治疗失败的慢性鼻塞患者,羟甲唑啉/布地奈德联合喷剂4周治疗的应答率显著高于单用布地奈德,且研究期间未见药物性鼻炎表现,全部成功停用羟甲唑啉。
研究设计与样本
- 单中心、双盲、随机临床试验,于2024年10月至2025年7月在华盛顿大学/巴恩斯犹太医院开展。
- 筛查87人,61人签署知情同意,60人随机并完成基线评估;联合组31例,单用布地奈德组29例。
- 纳入标准为成人慢性鼻塞、既往局部激素治疗失败且无慢性鼻窦炎。
- 干预为每日两次鼻喷,分别含羟甲唑啉/布地奈德或单用布地奈德,治疗4周后减量3周。
- 10例受试者于治疗前后行下鼻甲活检用于组织病理学分析。
主要发现
- 联合组应答者24/29(83%),单用布地奈德组10/28(36%),差异47个百分点(95%CI 25-70)。
- 应答定义为治疗4周后临床总体印象改善量表至少中度改善。
- 联合组治疗期间无受试者出现提示反跳性鼻塞的阻塞加重。
- 全部受试者均顺利停用羟甲唑啉。
关键数值与推荐
- 主要结局为治疗4周后临床总体印象改善量表至少中度改善的应答率。
- 反跳性鼻塞或减量困难通过临床总体印象严重度量表评分变化评估。
临床怎么用
- 对局部激素治疗失败的慢性鼻塞成人,可考虑羟甲唑啉/布地奈德联合治疗。
- 使用中需关注长期应用羟甲唑啉可能带来的反跳性鼻塞风险。
局限性
- 单中心研究,样本量有限。
- 研究期间未观察到药物性鼻炎,但更长疗程使用的反跳风险不能排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prolonged use of oxymetazoline, a highly effective nasal decongestant, is associated with rebound obstruction, but previous literature has shown potential for intranasal steroids to prevent tachyphylaxis and rebound, thereby potentially allowing for long-term combined oxymetazoline/intranasal steroid use in patients with chronic nasal obstruction. OBJECTIVE: To determine whether long-term combined oxymetazoline/budesonide nasal spray could alleviate the nasal obstruction associated with chronic rhinitis without inducing symptoms or histopathologic evidence of rhinitis medicamentosa. DESIGN, SETTING, AND PARTICIPANTS: This study was a single-center, double-blind, randomized clinical trial conducted at Washington University in St Louis/Barnes Jewish Hospital from October 2024 to July 2025. Key selection criteria included adults with chronic nasal obstruction, prior failure of topical steroids, and no chronic sinusitis. INTERVENTION: Participants used a provided nasal spray twice daily containing either oxymetazoline/budesonide or budesonide alone for 4 weeks of active treatment followed by a 3-week wean period. Ten participants underwent pretreatment and posttreatment inferior turbinate biopsies for histopathological analysis of change. MAIN OUTCOMES AND MEASURES: The primary outcome measure is the rate of responders, defined as at least moderate improvement on the Clinical Global Impressions-Improvement scale, assessed after 4 weeks of treatment. Measures of rebound obstruction or difficulty weaning were assessed by score changes on the Clinical Global Impression-Severity scale. RESULTS: From 87 individuals screened, 61 participants signed informed consent, and 60 participants were randomized and completed baseline assessments. Of the randomized participants, 31 participants received oxymetazoline/budesonide spray (mean [SD] age at enrollment, 46.0 [18.7] years; 18 [58.1%] female; 13 [41.9%] male), and 29 participants received budesonide alone (mean [SD] age, 51.2 [17.1] years; 17 [58.6%] female; 12 [41.4%] male). There were 24 of 29 (83%) responders to treatment in the oxymetazoline/budesonide arm, compared with 10 of 28 (36%) in the budesonide-only arm, a difference of 47 percentage points (95% CI, 25-70 percentage points). None of the participants in the oxymetazoline arm developed worsening obstruction concerning for rebound obstruction during active treatment. All successfully weaned off oxymetazoline without issue. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, there was a large and clinically meaningful greater proportion of responders in the oxymetazoline arm, without signs or symptoms of rhinitis medicamentosa during the study. All participants successfully weaned off oxymetazoline. For patients with chronic nasal obstruction failing topical steroids, chronic therapy with combination oxymetazoline/budesonide may be considered, though risks of rebound congestion with longer-term use cannot be excluded. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06830109.
引用
- Cruz L, Rammell J, Kallogjeri D, et al. Nasal Obstruction and Treatment With Oxymetazoline and Corticosteroids: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026. PMID: 42954986. doi:10.1001/jamaoto.2026.3297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。